Gene Editing FAQ

Bridge RNAs represent the most significant theoretical advance over CRISPR since prime editing and arguably the largest since base editing. They sit at the intersection of multiple traditions: the RNA-guided programmability of CRISPR, the strand-exchange chemistry of serine recombinases (the same enzyme family that powers PASTE — see our twin prime editing and PASTE article), and the structural insights of mobile genetic elements. Like all gene editing tools, bridge RNAs face the same delivery system challenges as CRISPR — and arguably worse, because the cargo is novel and large. The Arc Institute itself, founded by Patrick Hsu, Silvana Konermann, and Patrick Collison in 2021, was created in part to enable exactly this kind of high-risk, foundational discovery work, and was the home institution for the bridge RNA papers.

Type 1 diabetes (T1D) is one of the cruelest autoimmune diseases. The body's own immune system -- specifically autoreactive T cells -- systematically destroys the insulin-producing beta cells in the pancreatic islets of Langerhans. Once enough beta cells are gone, the body can no longer regulate blood glucose. Without exogenous insulin, death follows within weeks. With it, patients face a lifetime of relentless management: multiple daily injections or insulin pump therapy, continuous glucose monitoring, carbohydrate counting, and the constant threat of hypoglycemic episodes and long-term complications including cardiovascular disease, kidney failure, nerve damage, and blindness.

What it is: Transthyretin (ATTR) amyloidosis is a progressive, life-threatening disease caused by mutations in the TTR gene. The mutant transthyretin protein misfolds and accumulates as amyloid deposits in the heart, nerves, and other organs. Hereditary ATTR amyloidosis affects an estimated 50,000 people worldwide and causes debilitating peripheral neuropathy and cardiomyopathy. Without treatment, patients with cardiac involvement have a median survival of 2.5 to 3.5 years from diagnosis. Current treatments — including the RNA interference drug patisiran and the antisense oligonucleotide inotersen — require ongoing administration and slow disease progression but do not cure it.

In December 2023, the FDA approved Casgevy (exagamglogene autotemcel) — the first CRISPR-based therapy ever authorized for clinical use in the United States. Developed by Vertex Pharmaceuticals and CRISPR Therapeutics, it offered something that had never existed before: a functional cure for sickle cell disease (SCD), a devastating blood disorder that affects approximately 100,000 Americans and millions more worldwide. The clinical data was remarkable. In pivotal trials, 97% of treated patients were free of the excruciating vaso-occlusive crises that define the disease for at least 12 consecutive months after treatment.

Scientists considered many animal species before settling on pigs as the most promising organ source. Non-human primates — baboons, chimpanzees — were early candidates because of their close evolutionary relationship to humans. But primate organs are too small, primates breed slowly, and the ethical concerns around using our closest relatives proved insurmountable. In 1984, surgeon Leonard Bailey transplanted a baboon heart into a newborn infant known as "Baby Fae" at Loma Linda University Medical Center. The child survived 21 days before the organ was rejected. The case drew worldwide attention and intense criticism.

Twin prime editing (twinPE) was introduced by Andrew Anzalone, David Liu, and colleagues in Nature Biotechnology in 2022 ("Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing"). The trick is to use two pegRNAs that target opposite strands of the same locus, each writing a small piece of new sequence. The resulting nicks and edits cooperate to install matched recombination sites — typically attB or attP — flanking a region of interest. After twin prime editing has installed these "landing pads," the genomic locus is now a substrate for follow-on operations.

What it is: Hereditary angioedema (HAE) is a rare genetic disorder caused by mutations in the SERPING1 gene, which encodes C1-inhibitor, a protein that regulates the complement and contact activation systems. When C1-inhibitor is deficient or dysfunctional, patients experience sudden, unpredictable episodes of severe swelling (edema) in the face, throat, abdomen, and extremities. Throat swelling can be fatal if untreated. Approximately 1 in 50,000 people worldwide are affected. Current treatments require regular injections or infusions to prevent attacks — often every one to two weeks, indefinitely.

Every cell in your body carries the same three-billion-letter DNA sequence, yet a neuron looks and behaves nothing like a liver cell. The difference is not in the letters themselves but in which letters are being read. A vast regulatory layer — chemical tags on DNA, structural modifications to the proteins that package it, and small RNA molecules that fine-tune its expression — determines which genes are active and which are silent in any given cell at any given time. This regulatory layer is the epigenome, and epigenetic editing is the emerging discipline that seeks to rewrite it on demand.

What it is: Sickle cell disease (SCD) is caused by a single mutation in the HBB gene, which encodes the beta-globin protein in hemoglobin. This mutation causes red blood cells to deform into rigid, sickle-shaped cells that block blood vessels, triggering episodes of agonizing pain called vaso-occlusive crises (VOCs). SCD affects approximately 100,000 Americans and millions worldwide, disproportionately impacting people of African descent. Before gene therapy, the only curative option was a bone marrow transplant from a matched sibling donor — available to fewer than 20% of patients.

In June 2012, Jennifer Doudna of UC Berkeley and Emmanuelle Charpentier, then at Umea University in Sweden, published a paper in Science titled "A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity." The paper demonstrated that the CRISPR-Cas9 system — a naturally occurring immune defense in bacteria — could be reprogrammed to cut specific DNA sequences in a test tube. Critically, they showed that a single guide RNA (sgRNA) could be engineered to direct the Cas9 protein to virtually any target sequence, making the system remarkably simple and programmable.

What it is: Chronic granulomatous disease (CGD) is a rare inherited immune deficiency affecting approximately 1 in 200,000 to 250,000 people. It is caused by mutations in genes encoding components of the NADPH oxidase complex — most commonly the CYBB gene on the X chromosome (X-linked CGD). Patients' white blood cells cannot produce the reactive oxygen species needed to kill bacteria and fungi, leaving them vulnerable to severe, recurrent, and life-threatening infections. Patients require lifelong prophylactic antibiotics and antifungals, and many need bone marrow transplants.

While headlines about CRISPR tend to focus on human medicine, the technology is quietly transforming agriculture. Gene-edited crops are being grown commercially, gene-edited foods are on store shelves, and regulatory agencies around the world are grappling with how to classify them. Unlike the decades-long controversy over genetically modified organisms (GMOs), CRISPR-edited crops are entering the market with less public resistance -- in part because the technology works differently, and in part because regulators in several countries have decided to treat them differently.

The COVID-19 pandemic became the first real-world stress test for CRISPR diagnostics. When SARS-CoV-2 emerged in late 2019, the standard diagnostic was RT-qPCR -- a laboratory-based molecular test that amplifies viral RNA using a thermal cycler. RT-qPCR is highly accurate, but it requires expensive equipment, trained technicians, and centralized lab infrastructure. In the early months of the pandemic, testing bottlenecks became a global crisis. Labs were overwhelmed, turnaround times stretched to a week or more, and millions of people could not access testing at all.

To put Casgevy's commercial performance in perspective: Vertex Pharmaceuticals is a company that generates approximately $9 billion per year from its cystic fibrosis franchise (Trikafta/Kaftrio). Casgevy's $116 million in 2025 revenue represents roughly 1.3% of the company's total revenue. Initial analyst projections had estimated $2 billion to $4 billion in peak annual Casgevy revenue within five to seven years of launch. Those projections are now being revised to $500 million to $1.5 billion, with many analysts pushing peak revenue further into the future.

Editas Medicine, co-founded by CRISPR pioneer Feng Zhang, developed EDIT-101 — the first CRISPR medicine to be administered directly into the human body (in vivo). EDIT-101 consists of an AAV5 vector carrying the Staphylococcus aureus Cas9 (SaCas9) gene and two guide RNAs targeting the flanking regions of the CEP290 intronic mutation. SaCas9 was chosen because it is smaller than the more commonly used Streptococcus pyogenes Cas9 (SpCas9), allowing it to fit within the AAV packaging constraint along with the guide RNAs and necessary regulatory elements.

Adeno-associated viruses are small, non-pathogenic viruses that have become the delivery vehicle of choice for in vivo gene therapy. They are well-tolerated by the immune system (relative to other viral vectors), they can be engineered to target specific tissues through different serotypes (AAV8 for liver, AAV9 for the central nervous system, AAVrh10 for muscle, and so on), and several AAV-based gene therapies have already received regulatory approval — including Luxturna for inherited retinal dystrophy and Zolgensma for spinal muscular atrophy.

What it is: Duchenne muscular dystrophy (DMD) is one of the most common and devastating genetic diseases in children, affecting approximately 1 in 3,500 to 5,000 male births. It is caused by mutations in the DMD gene — the largest gene in the human genome — which encodes dystrophin, a protein essential for muscle fiber structural integrity. Without dystrophin, muscles progressively weaken and degenerate. Boys with DMD typically lose the ability to walk by age 10-12 and often die from cardiac or respiratory failure in their twenties or thirties.

Cancer has always been, at its core, a disease of the genome. Mutations accumulate, tumor suppressors fail, oncogenes activate, and cells begin to divide without restraint. For decades, oncology fought this genomic disease with blunt instruments -- chemotherapy that poisons dividing cells indiscriminately, radiation that burns tissue in a targeted radius, surgery that cuts away visible masses. These approaches saved millions of lives, but they were never precise enough to match the molecular complexity of the disease they were fighting.

When billions of people rolled up their sleeves for a COVID-19 vaccine in 2021, most had no idea they were participating in one of the largest proof-of-concept experiments in the history of genetic medicine. The Pfizer-BioNTech and Moderna vaccines did not merely protect against a virus. They validated a delivery platform -- lipid nanoparticles carrying messenger RNA -- that scientists had been quietly developing for decades. That platform is now being repurposed to deliver gene-editing tools directly into the human body.

What it is: Hemophilia B is an X-linked bleeding disorder caused by mutations in the F9 gene, which encodes clotting factor IX. Without sufficient factor IX, patients experience spontaneous and prolonged bleeding episodes, particularly into joints, muscles, and internal organs. Severe hemophilia B affects approximately 1 in 25,000 male births. For decades, treatment has required regular intravenous infusions of factor IX replacement — typically every one to two weeks — at a lifetime cost estimated at $20 million or more.

It is impossible to discuss Casgevy's access crisis without confronting the racial dynamics embedded in it. Sickle cell disease overwhelmingly affects Black Americans. Approximately 1 in 365 Black or African American babies is born with SCD, compared to roughly 1 in 16,300 Hispanic American births and negligible rates in white populations. This is because the sickle cell trait evolved as a protective adaptation against malaria in populations of sub-Saharan African, Mediterranean, Middle Eastern, and South Asian descent.

CAR-T cell therapy is one of the great success stories of modern medicine. Patients with aggressive blood cancers who had failed every available treatment -- chemotherapy, radiation, stem cell transplants, targeted drugs -- received a single infusion of genetically engineered T cells and walked out of the hospital in remission. Some of them are still cancer-free years later. The FDA has approved six CAR-T products since 2017, and the clinical results in certain blood cancers remain among the most impressive in oncology.

What it is: Beta-thalassemia is a group of inherited blood disorders caused by mutations in the HBB gene that reduce or eliminate production of beta-globin, a key component of hemoglobin. In its most severe form — transfusion-dependent beta-thalassemia (TDT) — patients require blood transfusions every two to four weeks from early childhood to survive. Without transfusions, severe anemia leads to organ damage and death. Chronic transfusions cause iron overload, which itself damages the heart, liver, and endocrine organs.

In the United States, gene-edited foods that fall under the USDA SECURE rule exemption are not required to carry a "gene-edited" label. The National Bioengineered Food Disclosure Standard, which went into effect in 2022, requires labeling for foods that contain detectable modified genetic material from transgenic processes. But because most gene-edited crops do not contain foreign DNA — and the edits are often undetectable with standard testing methods — they fall outside the scope of this labeling law.

To understand why AI has become indispensable, consider the numbers. A standard 20-nucleotide CRISPR guide RNA has 4^20 possible sequences, roughly one trillion. For prime editing, the design space is orders of magnitude larger: a prime editing guide RNA (pegRNA) must specify not only the target site but also the reverse transcription template, the primer binding site length, and optional structural modifications. The number of possible pegRNA designs for a single target edit can exceed millions.

These three tools are not competitors so much as complementary layers in an expanding toolkit. The optimal choice depends on the specific biological question, the target tissue, the nature of the mutation, and the acceptable risk profile. As delivery methods improve and editing efficiencies increase, the boundaries between what each tool can accomplish will continue to blur — but understanding their fundamental differences remains essential for anyone working at the frontier of genetic medicine.

When most people hear "CRISPR," they picture molecular scissors snipping DNA to cure genetic diseases. That image is accurate but incomplete. Some of the most impactful applications of CRISPR technology have nothing to do with editing genes at all. Instead, they harness the same molecular machinery to detect specific genetic sequences -- and in doing so, they are building a new generation of diagnostic tools that could be faster, cheaper, and more portable than anything that currently exists.

The CRISPR-Cas9 system relies on a guide RNA (gRNA) — a short RNA molecule, typically 20 nucleotides long, that directs the Cas9 protein to its target site through Watson-Crick base pairing. In a perfect world, the guide RNA would only bind to the one genomic location that perfectly matches its sequence. The human genome, however, contains roughly 3.2 billion base pairs. With a 20-nucleotide targeting sequence, there are inevitably other sites in the genome that share partial complementarity.

Compact editors are not a replacement for SpCas9 — they are a complementary layer in a maturing editor toolbox. SpCas9 remains the workhorse for ex vivo editing, where cargo size is irrelevant and LNPs handle delivery. Compact editors dominate where delivery is constrained: in vivo, AAV, and tissues outside the liver. Base editors and prime editors built on compact chassis (a particularly active research area in 2024–2025) promise the precision of base editing with the deliverability of AAV.

On a spring day in May 2025, a patient at a medical center received an infusion of their own bone marrow stem cells — cells that had been removed, corrected at a single point in their DNA, and returned to their body. This was not the first gene therapy. It was not the first time CRISPR technology had been used in a person. But it was a genuine first of its kind: the first time prime editing — the most precise and versatile form of gene editing ever devised — had been tested in a human being.

Base editing, developed by David Liu's lab at the Broad Institute, avoids creating double-strand breaks entirely. Cytosine base editors (CBEs) convert C-to-T, and adenine base editors (ABEs) convert A-to-G, using a catalytically impaired Cas9 (nickase) fused to a deaminase enzyme. Because base editors only nick one DNA strand rather than cutting both, they dramatically reduce the formation of indels, large deletions, and chromosomal rearrangements at both on-target and off-target sites.

Imagine living with a condition where, at any moment, your body could turn against you. Your face swells shut. Your hands balloon to twice their size. Your abdomen fills with fluid, producing pain so severe it sends you to the emergency room. These attacks arrive unpredictably -- sometimes weekly, sometimes monthly -- and any one of them could be fatal if the swelling blocks your airway. This is the reality for roughly 50,000 people worldwide living with hereditary angioedema (HAE).

A retron is a bacterial genetic element discovered in the 1980s in Myxococcus xanthus. It encodes three things on a single transcript: a non-coding RNA (msr-msd), a reverse transcriptase (RT), and — in many cases — an effector protein. The reverse transcriptase uses part of its own non-coding RNA as a template to synthesize a hybrid RNA-DNA molecule called multi-copy single-stranded DNA, or msDNA. Each retron-bearing bacterial cell can contain hundreds to thousands of msDNA copies.

When Jennifer Doudna and Emmanuelle Charpentier published their landmark paper in Science in June 2012, they did more than describe a new way to edit genes. They lit the fuse on what would become the most consequential patent fight in the history of biotechnology — a legal battle that would span more than a decade, cross international borders, reshape the pharmaceutical industry, and force uncomfortable questions about who truly "owns" a technology that could redefine medicine.

On December 8, 2023, the U.S. Food and Drug Administration did something unprecedented: it approved two gene therapies for sickle cell disease on the same day. Casgevy (exagamglogene autotemcel), developed by Vertex Pharmaceuticals and CRISPR Therapeutics, became the first CRISPR-based therapy ever approved in the United States. Hours later, Lyfgenia (lovotibeglogene autotemcel), developed by bluebird bio, received its own approval using a completely different genetic approach.

For the past decade, gene editing has been synonymous with permanence. CRISPR-Cas9, base editing, and prime editing all share one fundamental trait: they alter the DNA itself, rewriting the genome in a way that persists through every cell division for the rest of a patient's life. That permanence is both the greatest strength and the greatest liability of DNA editing. If the edit is correct, the patient may be cured forever. If something goes wrong, there is no undo button.

What it is: Spinal muscular atrophy (SMA) is a devastating neuromuscular disease caused by mutations in the SMN1 gene, which encodes the survival motor neuron protein. Without functional SMN protein, motor neurons in the spinal cord progressively degenerate, leading to muscle weakness, paralysis, and — in the most severe form (Type 1) — death before age two. SMA affects approximately 1 in 10,000 live births and was historically the leading genetic cause of death in infants.

Verve Therapeutics, founded in 2018 by cardiologist Sekar Kathiresan, was built on a single bold idea: use base editing to permanently turn off the PCSK9 gene in the liver, achieving lifelong cholesterol reduction with one injection. Kathiresan, who had spent his career studying the genetics of heart disease at the Broad Institute and Massachusetts General Hospital, recognized that the natural human genetics data pointed clearly toward PCSK9 as a safe and effective target.

GLP-1 drugs are not a cure. They are a treatment that requires indefinite continuation. When patients stop taking semaglutide or tirzepatide, the weight comes back. In the STEP 1 trial extension study, published in the journal Diabetes, Obesity and Metabolism, participants who discontinued semaglutide regained roughly two-thirds of their lost weight within a year. Their appetite returned, their metabolic benefits faded, and their cardiometabolic risk factors worsened.

Therapeutic RNA knockdown. This is the area moving fastest. Locanabio (acquired by Vertex in 2024) developed RNA-targeting CRISPR therapies for Huntington's disease and myotonic dystrophy using CasRx-based knockdown of toxic repeat-containing RNAs. Editas Medicine has also disclosed an RNA-targeting program. The appeal is straightforward: Cas13 silences disease RNAs reversibly and never touches the genome — no off-target indels, no large deletions, no p53 activation.

Bridge RNAs are non-coding RNAs encoded by IS110-family insertion sequences — a class of mobile genetic elements in bacteria that have been known for decades but whose mobilization mechanism was a mystery. The Hsu lab showed that IS110 transposases use a structured "bridge RNA" with two binding loops: one that base-pairs with the target DNA (the site where the IS110 element will insert) and another that base-pairs with the donor DNA (the IS110 element itself).

The regulatory landscape for gene-edited animals is complex and evolving. In the United States, the FDA regulates intentional genomic alterations (IGAs) in animals under the same framework used for new animal drugs. This means that a gene-edited cow must go through a regulatory review similar to that of a new veterinary pharmaceutical — a process that critics argue is disproportionately burdensome for edits that introduce naturally occurring genetic variants.

Sickle cell disease is caused by a single-letter mutation in the HBB gene, which encodes the beta-globin subunit of hemoglobin. The mutation causes hemoglobin molecules to polymerize under low-oxygen conditions, distorting red blood cells into rigid, crescent-shaped "sickles." These misshapen cells block small blood vessels, causing excruciating pain episodes called vaso-occlusive crises (VOCs), organ damage, stroke, and a significantly shortened lifespan.

Every mainstream gene editing tool — CRISPR-Cas9, base editing, prime editing — writes changes directly into the DNA. Those changes are permanent and heritable within cell lineages. RNA editing, by contrast, modifies the messenger RNA (mRNA) that the cell transcribes from DNA. Because mRNA is a transient molecule with a lifespan measured in hours to days, any edit made at the RNA level is inherently temporary. The underlying DNA remains completely intact.

While CRISPR targets the genetic root cause of retinal disease, another approach takes a fundamentally different strategy: optogenetics. Retinitis pigmentosa (RP) is a group of inherited retinal diseases affecting roughly 1 in 4,000 people worldwide. RP is genetically heterogeneous — over 80 genes can cause it — and is characterized by progressive degeneration of rod photoreceptors followed by cone loss, leading to tunnel vision and eventually blindness.

CRISPRa was developed in parallel with CRISPRi by the Weissman/Lim and Zhang labs in 2013. Like CRISPRi, it relies on a catalytically dead Cas9 (dCas9, with the D10A and H840A mutations) that retains DNA binding but loses cutting activity. Unlike CRISPRi, CRISPRa is fused to transcriptional activator domains that recruit the cellular machinery needed to drive expression — RNA polymerase II, Mediator, chromatin remodelers, and histone acetyltransferases.

Walk through the produce aisle of certain grocery stores today and you might pick up a salad mix that was developed using CRISPR gene editing. No special label tells you so. No warning sticker. No asterisk. That is because, under current regulations in the United States, Japan, and several other countries, gene-edited foods are treated differently from genetically modified organisms (GMOs). And there are good scientific reasons for that distinction.

In 2012, two scientists — Emmanuelle Charpentier and Jennifer Doudna — published a paper that would reshape the life sciences. They demonstrated that a bacterial immune system called CRISPR could be reprogrammed to cut any DNA sequence with remarkable precision. Within a few years, laboratories worldwide adopted CRISPR-Cas9 as their primary gene editing tool, and in 2020, Charpentier and Doudna received the Nobel Prize in Chemistry for their work.

Cardiovascular disease (CVD) remains the number-one killer globally, responsible for an estimated 17.9 million deaths per year according to the World Health Organization. In the United States alone, someone has a heart attack every 40 seconds. The economic burden is staggering — the American Heart Association estimates that CVD costs the U.S. healthcare system more than $400 billion annually in direct medical expenses and lost productivity.

The idea behind gene editing for obesity is conceptually the same as what is already being pursued for cholesterol. Just as companies like Verve Therapeutics and CRISPR Therapeutics are developing single-injection gene editing treatments to permanently lower LDL cholesterol by editing genes in the liver, a parallel approach could theoretically be applied to the metabolic pathways that control appetite, fat storage, and energy expenditure.

Verve's journey to the clinic began with VERVE-101, the company's first-generation base editing therapy targeting PCSK9. The Heart-1 trial (NCT05398029), launched in 2022, was a first-in-human, Phase 1 dose-escalation study conducted primarily in New Zealand and the United Kingdom. It enrolled adults with HeFH and established atherosclerotic cardiovascular disease (ASCVD) who were already on maximally tolerated lipid-lowering therapy.

CasX was discovered through metagenomic sequencing of groundwater samples from Deltaproteobacteria and Planctomycetes. Liu, Knott, and colleagues (Doudna lab, Nature 2019) showed it was an RNA-guided nuclease of roughly 980 amino acids — about 30 percent smaller than SpCas9 — with a distinct structural fold and minimal homology to Cas9 or Cas12a. Crucially, it retained robust genome editing in human cells while targeting a TTCN PAM.

CRISPRi was introduced by Lei Stanley Qi, Jonathan Weissman, Wendell Lim, and colleagues in a landmark 2013 Cell paper ("Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression"). The team mutated the two catalytic residues of Streptococcus pyogenes Cas9 — D10A in the RuvC domain and H840A in the HNH domain — to create a "dead Cas9" (dCas9) that retains DNA-binding activity but cannot cleave.

In 2024, a team led by Lei Stanley Qi at Stanford published CRISPR-GPT in Nature Biomedical Engineering, introducing a large language model (LLM) agent specifically designed to assist with the design and execution of gene editing experiments. CRISPR-GPT integrates domain-specific knowledge about CRISPR systems with the general reasoning capabilities of large language models, enabling it to assist researchers with tasks including:

CAR-T cell therapy -- in which a patient's T cells are extracted, engineered to express a chimeric antigen receptor that targets cancer, and infused back into the body -- was already one of the most important advances in cancer treatment before CRISPR entered the picture. Products like Kymriah and Yescarta demonstrated that engineered immune cells could achieve durable remissions in patients who had exhausted all other options.

Cas13 was discovered by Omar Abudayyeh, Jonathan Gootenberg, Feng Zhang, and colleagues, reported in Science in June 2016 ("C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector"). The enzyme — initially called C2c2, later renamed Cas13 — is a Class 2, Type VI CRISPR effector that uses a single crRNA to find and cleave complementary RNA. Unlike Cas9 and Cas12, Cas13 has nothing to do with DNA at all.

Tune Therapeutics, founded in 2021 and headquartered in Durham, North Carolina, has become the first company to bring an epigenetic editing therapy into human clinical trials. The company was co-founded by Charles Gersbach of Duke University, a pioneer in the development of epigenetic effector proteins, along with Fyodor Urnov of the Innovative Genomics Institute and Michael Ehlers, a former Biogen executive who serves as CEO.

Cardiovascular disease kills more people than any other cause on Earth. According to the World Health Organization, an estimated 17.9 million people die from cardiovascular conditions every year, accounting for roughly 32% of all global deaths. In the United States alone, heart disease claims approximately 700,000 lives annually, making it the leading cause of death for both men and women across most racial and ethnic groups.

In a move that sent shockwaves through the pharmaceutical industry, Eli Lilly entered a major partnership with Verve Therapeutics, gaining rights to VERVE-102 and Verve's broader cardiovascular gene-editing pipeline. The deal, valued at up to several billion dollars including upfront payment and milestone-based payments, represented one of the largest investments by a major pharmaceutical company in the gene-editing space.

The idea that transplanting insulin-producing cells could cure T1D is not new. Cadaveric islet transplantation has been performed for over two decades, with the landmark Edmonton Protocol, published in 2000 by Dr. James Shapiro and colleagues at the University of Alberta, demonstrating that transplanted islets from deceased donors could achieve insulin independence in patients with severe T1D (Shapiro et al., NEJM, 2000).

Imagine you have a long book — three billion characters long — and somewhere in that book, a single letter is wrong. That typo causes a disease. Traditional gene editing tools like CRISPR-Cas9 work by cutting the page at that spot and hoping the cell's repair machinery fixes it correctly. Base editing takes a different approach: it chemically converts one DNA letter into another, without ever cutting the double helix.

RNA editing is still in its early clinical stages, but the trajectory is promising. As guide RNA chemistry improves, editing efficiency rises, and delivery to diverse tissues matures, RNA editing could become the preferred approach for a significant subset of genetic diseases — particularly those where reversibility is valued, chronic dosing is acceptable, and the mutation involves a single A-to-G correctable change.

Gene editing has evolved rapidly since CRISPR-Cas9 first demonstrated that targeted DNA cuts were possible. Today, scientists have three major editing strategies at their disposal, each with distinct mechanisms, capabilities, and trade-offs. Understanding the differences between CRISPR-Cas9, base editing, and prime editing is essential for anyone following the field — whether in the clinic, the lab, or the market.

Gene editing raises complex animal welfare questions. On one hand, creating disease-resistant animals could dramatically reduce suffering — no more PRRS outbreaks in pig barns, no more painful dehorning of cattle. On the other hand, critics worry that gene editing could be used to push animals further toward extreme productivity (even faster growth, even higher milk yields) in ways that compromise their wellbeing.

In the span of just a few years, a class of drugs known as GLP-1 receptor agonists has fundamentally changed how medicine thinks about obesity. Semaglutide, sold as Ozempic for diabetes and Wegovy for weight loss, along with tirzepatide (Mounjaro and Zepbound), has delivered something doctors had struggled to achieve for decades: reliable, significant, sustained weight loss in the majority of patients who take it.

Inherited retinal diseases collectively affect roughly 2 million people worldwide. Age-related macular degeneration (AMD) affects over 200 million. AMD is the leading cause of irreversible vision loss in people over 50 in the developed world, and the wet (neovascular) form — in which abnormal blood vessels grow beneath the retina, leaking fluid and blood — is responsible for the most severe and rapid vision loss.

The earliest and most mature application of AI in gene editing is the computational design of guide RNAs. First-generation tools used relatively simple regression models trained on experimental data from CRISPR screens. These models identified sequence features -- such as GC content, nucleotide preferences at specific positions, and secondary structure -- that correlated with high on-target editing efficiency.

When most people think of CRISPR, they picture scientists in labs editing human cells to cure diseases. But some of the most dramatic — and commercially advanced — applications of gene editing are happening in animals. Farmers are breeding heat-tolerant cattle for a warming planet. Surgeons are transplanting pig kidneys into human patients. And one ambitious company is trying to bring back the woolly mammoth.

To understand why gene editing might work for Alzheimer's, you first need to understand the disease's genetic landscape. Alzheimer's is not a single disease with a single cause. It exists on a spectrum, from rare early-onset familial forms driven by powerful single-gene mutations to the far more common late-onset form shaped by dozens of genetic risk factors interacting with age, lifestyle, and environment.

Luxturna demonstrated that gene addition via AAV could work beautifully in the eye. But it also exposed a fundamental limitation: AAV vectors have a packaging capacity of approximately 4.7 kilobases. Any therapeutic gene — including its promoter and regulatory elements — must fit within this constraint. For RPE65, which has a relatively compact coding sequence of about 1.6 kilobases, this was not a problem.

Statins have been the backbone of cholesterol management since lovastatin was approved in 1987. Drugs like atorvastatin (Lipitor) and rosuvastatin (Crestor) work by inhibiting HMG-CoA reductase, an enzyme the liver uses to produce cholesterol. They are cheap, well-studied, and effective, reducing LDL-C by 30-50% on average. By some estimates, statins have saved millions of lives over the past four decades.

When CRISPR-Cas9 edits DNA, it uses a short guide RNA to find a specific sequence in the genome. The Cas9 protein then cuts both strands of the DNA at that location. The cell's own repair machinery then fixes the break, either by stitching the ends together (a process called non-homologous end joining, or NHEJ) or by using a supplied DNA template to make a precise edit (homology-directed repair, or HDR).

Leber hereditary optic neuropathy (LHON) is a maternally inherited mitochondrial disease that causes sudden, painless vision loss in young adults, predominantly males. It is caused by mutations in mitochondrial DNA — most commonly m.11778G>A in the ND4 gene — that impair Complex I of the mitochondrial electron transport chain, leading to selective death of retinal ganglion cells and optic nerve atrophy.

Chronic granulomatous disease is a rare inherited immune disorder affecting approximately 1 in 200,000 to 1 in 250,000 people. It is caused by mutations in genes encoding subunits of the NADPH oxidase complex, an enzyme system that neutrophils and other phagocytes use to generate reactive oxygen species — the chemical weapons these immune cells deploy to kill bacteria and fungi after engulfing them.

CRISPR-Cas9 uses a guide RNA to direct the Cas9 nuclease to a specific genomic location, where it creates a double-strand break (DSB). The cell then repairs the break through one of two pathways: non-homologous end joining (NHEJ), which typically introduces insertions or deletions that disrupt the gene, or homology-directed repair (HDR), which uses a supplied DNA template to make a precise edit.

Casgevy is not the only gene therapy approved for sickle cell disease. On the same day in December 2023, the FDA also approved Lyfgenia (lovotibeglogene autotemcel), developed by bluebird bio. Lyfgenia uses a lentiviral vector rather than CRISPR to introduce a modified hemoglobin gene (HBB-T87Q) into the patient's stem cells. Its list price is $3.1 million — nearly $1 million more than Casgevy.

The COVID vaccines would not exist without a discovery made in 2005 by Katalin Kariko and Drew Weissman at the University of Pennsylvania. For years, researchers had struggled with a fundamental problem: synthetic mRNA injected into the body triggered a violent inflammatory immune response. The immune system recognized the foreign mRNA and attacked it before it could be translated into protein.

Anti-CRISPR proteins were first reported by Joe Bondy-Denomy, Alan Davidson, Karen Maxwell, and colleagues in Nature in 2013 ("Bacteriophage genes that inactivate the CRISPR/Cas bacterial immune system"). The team studied phages of Pseudomonas aeruginosa that evaded a Type I-F CRISPR system and found small phage genes — initially anonymous open reading frames — that abolished CRISPR activity.

Cas12a was discovered by Bernd Zetsche, Jonathan Strecker, Feng Zhang, and colleagues, reported in Cell in October 2015 ("Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System"). The enzyme was originally named Cpf1 (CRISPR from Prevotella and Francisella 1) and later renamed Cas12a to fit the unified CRISPR nomenclature established by the Koonin–Makarova classification.

On January 7, 2022, surgeons at the University of Maryland Medical Center performed the first transplant of a genetically modified pig heart into a living human patient. David Bennett Sr., a 57-year-old handyman from Maryland, was dying of heart failure and had been rejected from conventional transplant lists because of his poor health and history of non-compliance with medical protocols.

Caribou Biosciences, a company spun out of Jennifer Doudna's lab at UC Berkeley, uses a proprietary gene editing platform called chRDNA (CRISPR hybrid RNA-DNA guides). Unlike standard CRISPR guide RNAs that are composed entirely of RNA, chRDNA guides incorporate DNA nucleotides at specific positions, which Caribou reports improves specificity and reduces off-target editing [10].

Detecting off-target edits is technically demanding. You are looking for rare mutations — sometimes occurring in fewer than 0.1% of cells — scattered across 3.2 billion bases. Over the past decade, researchers have developed an arsenal of increasingly sensitive methods. Each has different strengths, and a thorough off-target analysis typically employs multiple approaches.

Every gene editing technology discussed in mainstream science coverage — CRISPR-Cas9, base editing, prime editing — makes permanent changes to the genome. That permanence is a feature when correcting a clear-cut genetic defect, but it is also a risk. An off-target edit in DNA is irreversible: once a gene is mutated, it stays mutated in that cell and all its descendants.

A compact CRISPR editor is any RNA-guided nuclease (or nickase) small enough to fit comfortably inside a single AAV vector together with its guide RNA and the regulatory machinery needed to drive expression in target tissue. In practice, "compact" usually means under 1,000 amino acids, or roughly 3 kb of coding sequence — about 25 to 60 percent the size of SpCas9.

Sometimes nature provides the most compelling evidence that a therapeutic strategy can work. In November 2019, a case report published in Nature Medicine described a woman from the Colombian PSEN1 E280A kindred — the same family where members almost invariably develop Alzheimer's dementia by their late forties — who remained cognitively intact until her seventies.

China has been at the forefront of CRISPR-based cancer immunotherapy since 2016, when Sichuan University conducted the world's first human CRISPR trial -- injecting PD-1-knocked-out T cells into a patient with metastatic non-small cell lung cancer. Since then, Chinese researchers have accumulated the largest clinical dataset on PD-1-edited immune cells in cancer.

In 2016, David Liu's laboratory at the Broad Institute introduced base editors — a fundamentally different approach that modifies individual DNA bases without creating double-strand breaks. The insight was to fuse a catalytically impaired Cas9 (called a nickase, which cuts only one DNA strand) to a deaminase enzyme that chemically converts one base into another.

The most important advantage is that RNA edits are temporary. mRNA has a half-life measured in hours to days. When the guide RNA or ASO is cleared from the cell, editing ceases, and normal mRNA is produced from the unchanged DNA. This creates an inherently safer therapeutic profile — dosing can be adjusted, and treatment can be stopped if adverse effects emerge.

Casgevy's list price is $2.2 million per patient. This is the wholesale acquisition cost of the therapy itself. It does not include hospitalization, chemotherapy, apheresis, follow-up care, travel, or lost wages. When all associated medical costs are factored in, the total cost of Casgevy treatment has been estimated at $2.7 million to $3.0 million per patient.

For most of pharmaceutical history, the logic of drug development has been straightforward: find a disease that affects many people, develop a treatment, test it in large clinical trials, and bring it to market. The larger the patient population, the better the economics. Rare diseases, by definition, break this model. Ultra-rare diseases shatter it entirely.

Cellectis predates the CRISPR era in allogeneic CAR-T development. The company's TALEN (Transcription Activator-Like Effector Nuclease) gene editing technology was one of the first precision editing tools to be applied to donor T cells, and Cellectis has been developing allogeneic CAR-T products since 2011 -- years before most competitors entered the space.

Every cell in your body carries the same DNA — roughly 3 billion base pairs encoding about 20,000 genes. Yet a neuron behaves nothing like a liver cell. The difference lies not in the DNA sequence itself but in the epigenome: the constellation of chemical tags and structural modifications that determine which genes are switched on or off in any given cell.

The application of AI to gene editing extends beyond molecular design into the clinical development process itself. Gene therapy clinical trials face distinctive challenges: small patient populations (many genetic diseases are rare), heterogeneous disease presentation, complex dosing decisions, and long follow-up periods to assess durability of effect.

The numbers tell a story of quiet, ongoing catastrophe. According to the Organ Procurement and Transplantation Network (OPTN), 104,954 candidates were on the national transplant waiting list as of January 2024. Kidneys account for the largest share — about 89,000 of those waiting need a kidney. Livers, hearts, and lungs make up most of the remainder.

One of the most important and least understood aspects of clinical trial participation is cost. In the vast majority of gene editing clinical trials, the experimental therapy itself is provided at no cost to the patient. The pharmaceutical company sponsoring the trial covers the cost of the drug, the manufacturing, and the study-related procedures.

Under U.S. patent law as it existed before 2013 (when the America Invents Act transitioned the system to "first to file"), the critical question was not who filed first, but who invented first. When two parties claimed to have invented the same thing, the USPTO could declare an "interference" — a legal proceeding to determine priority of invention.

A clinical trial is a structured research study that tests whether a treatment is safe and effective in people. For gene editing therapies, clinical trials are the path between the laboratory and the pharmacy. Every CRISPR therapy that eventually reaches patients — Casgevy for sickle cell disease, for example — went through this process first.

In late 2025, pharmaceutical giant Eli Lilly announced an agreement to acquire Verve Therapeutics for approximately $1.3 billion. The acquisition signaled something important: one of the world's largest and most sophisticated drug companies had looked at the gene editing approach to cardiovascular disease and decided it was worth a major bet.

Beyond therapeutics and agriculture, CRISPR has become an indispensable research tool. Scientists use it to create animal models of human diseases, perform large-scale genetic screens to identify the function of thousands of genes simultaneously, and study the fundamental mechanisms of biology with a precision that was previously impossible.

In January 2026, a team at the University of New South Wales (UNSW) Sydney published research that electrified the gene therapy community. Using epigenetic editing, they demonstrated that removing methyl tags from specific regulatory regions could reactivate HBF — the gene encoding fetal hemoglobin (HbF) — in adult red blood cell precursors.

RNA editing takes an entirely different approach. Instead of modifying the genome, it modifies the messenger RNA (mRNA) transcripts that carry genetic instructions from DNA to the cell's protein factories. Because RNA is naturally short-lived (most mRNA molecules are degraded within hours to days), any edits to RNA are inherently temporary.

All of the approaches discussed so far share a common feature: T cells are edited outside the body (ex vivo), then infused back into the patient. This requires cell collection, manufacturing facilities, and a multi-step production process. The logical next question is whether the same editing can be done directly inside the patient's body.

Perhaps the most frequently raised concern about designer babies is the potential for germline editing to exacerbate existing social inequalities. The worry is straightforward: if genetic enhancement becomes possible, the wealthy will access it first, and possibly exclusively, creating a new axis of inequality rooted in biology itself.

The concept is elegant in its simplicity. Several genes in the liver regulate how much cholesterol and other lipids circulate in the blood. If you could permanently alter one of those genes — disabling it in a targeted, controlled way — you could achieve a lasting reduction in LDL-C or other atherogenic lipids with a single treatment.

There are currently approximately 50 authorized treatment centers for Casgevy in the United States. These centers are concentrated in major metropolitan areas, primarily on the coasts and in the Southeast. This means that patients in rural areas — where a disproportionate share of SCD patients live — face enormous geographic barriers.

Intellia Therapeutics was co-founded in 2014 by Jennifer Doudna, the UC Berkeley biochemist who co-invented CRISPR-Cas9 gene editing and received the 2020 Nobel Prize in Chemistry alongside Emmanuelle Charpentier. Doudna's foundational intellectual property forms part of the bedrock on which Intellia's technology platform is built.

If Tune Therapeutics represents one pole of the epigenetic editing landscape, Chroma Medicine represents another. Co-founded in 2021 by David Liu — the Harvard chemist who invented both base editing and prime editing — Chroma is developing a suite of epigenetic editing tools that emphasize gene activation as well as gene silencing.

The first critical breakthrough was learning to make beta cells from stem cells. If you can derive unlimited quantities of functional, glucose-responsive beta cells from human pluripotent stem cells -- either embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) -- you eliminate the donor scarcity problem entirely.

One of the biggest selling points of traditional CRISPR is also one of its biggest risks: permanence. Once Cas9 cuts and the cell repairs the break, the edit is locked in forever. For diseases caused by a single well-understood mutation — like sickle cell disease — that permanence is a feature, not a bug. One treatment, one cure.

In 2019, David Liu's lab unveiled prime editing, which they described as a "search-and-replace" tool for the genome. Prime editors use a Cas9 nickase fused to a reverse transcriptase enzyme. The guide RNA — called a prime editing guide RNA (pegRNA) — contains both a targeting sequence and a template encoding the desired edit.

Getting gene editing components into the right cells in a living patient remains one of the field's greatest challenges. The two dominant delivery strategies -- adeno-associated virus (AAV) vectors and lipid nanoparticles (LNPs) -- both present large optimization problems that are well suited to machine learning approaches.

CRISPR Therapeutics, co-founded by Emmanuelle Charpentier, has emerged as one of the front-runners in allogeneic CAR-T development. The company's lead oncology program, CTX112 (zugo-cel), targets CD19 -- the same antigen pursued by Kymriah and Yescarta -- but does so using an off-the-shelf, CRISPR-edited allogeneic product.

Gene drives are perhaps the most powerful — and controversial — application of CRISPR in animals. A gene drive is a genetic system that ensures a particular gene is inherited by nearly 100% of offspring, rather than the usual 50%. Over multiple generations, a gene drive can spread a trait through an entire wild population.

The case for CRISPR in agriculture goes beyond consumer products. The world's population is projected to reach nearly 10 billion by 2050, and climate change is making agriculture more difficult. Rising temperatures, shifting rainfall patterns, emerging crop diseases, and shrinking arable land all threaten food production.

Off-target editing -- where the CRISPR complex cuts or edits unintended genomic sites -- is the central safety concern for therapeutic gene editing. Predicting off-target activity has been a focus of computational biology since the earliest days of CRISPR, but deep learning has substantially advanced the state of the art.

In 2020, the United States Department of Agriculture finalized its SECURE rule (Sustainable, Ecological, Consistent, Uniform, Responsible, Efficient), which updated how the agency regulates genetically engineered plants. The rule, which took full effect in 2021, fundamentally changed the landscape for gene-edited crops.

Founded in 2017 by Jennifer Doudna, Janice Chen, Lucas Harrington, and Trevor Martin, Mammoth Biosciences is the commercial vehicle for DETECTR technology. The company has raised over $400 million in venture funding and has positioned itself as a broad CRISPR platform company spanning both diagnostics and therapeutics.

While not specific to CRISPR, the safety of gene therapy delivery vehicles is inseparable from the overall safety equation. Many gene therapies use adeno-associated virus (AAV) vectors to deliver genetic material to target cells. AAV-based therapies have their own distinct risk profile that is important to understand.

Public attitudes toward gene-edited foods are nuanced and evolving. Surveys consistently show that consumers are more accepting of gene editing that modifies a plant's own genes than of transgenic GMOs that introduce foreign DNA. The "no foreign DNA" distinction resonates with public intuitions about what is natural.

No company has done more to advance in vivo CRISPR gene editing than Intellia Therapeutics, a Cambridge, Massachusetts-based biotech co-founded by CRISPR pioneer Jennifer Doudna. Intellia's two lead programs — NTLA-2001 and NTLA-2002 — have produced the most mature clinical data for any in vivo gene editing therapy.

One of the most compelling clinical stories in the allogeneic space comes not from CRISPR-Cas9 but from base editing. BE-CAR7, developed by a team at Great Ormond Street Hospital in London, uses cytosine base editors to engineer allogeneic CAR-T cells for the treatment of T-cell acute lymphoblastic leukemia (T-ALL).

There is a significant challenge facing LNP-CRISPR therapy: the liver problem. When administered intravenously, conventional LNPs overwhelmingly accumulate in the liver. This is because apolipoprotein E (ApoE) in the bloodstream adsorbs onto the LNP surface and directs the particles to ApoE receptors on hepatocytes.

Prime editing, also from David Liu's lab and published in Nature in 2019, represents the most precise editing approach currently available. The system uses a Cas9 nickase fused to a reverse transcriptase, guided by a prime editing guide RNA (pegRNA) that both specifies the target site and encodes the desired edit.

Every time Cas9 cuts DNA, there is a chance it cuts in the wrong place. These off-target effects can disrupt healthy genes, potentially triggering cancer or other problems. The field has developed high-fidelity Cas9 variants and better guide RNA designs to minimize this risk, but it cannot be eliminated entirely.

ClinicalTrials.gov is the primary database for finding clinical trials in the United States and many international studies. It is maintained by the National Library of Medicine at the U.S. National Institutes of Health. Every clinical trial conducted in the United States is legally required to be registered here.

The company that first proved LNP-delivered CRISPR could work inside the human body was Intellia Therapeutics, co-founded by Jennifer Doudna. In June 2021 -- while COVID vaccines were still being distributed worldwide -- Intellia reported interim results from the first clinical trial of an in vivo CRISPR therapy.

Public discussion of designer babies is often colored by science fiction scenarios that far outstrip current scientific capabilities. It is important to distinguish between what is technically possible now, what might become possible with foreseeable advances, and what remains firmly in the realm of speculation.

One of the most significant barriers to N-of-1 therapies has been regulatory. The FDA's traditional drug approval process requires extensive preclinical data, phased clinical trials, and statistical evidence of safety and efficacy across a patient population. None of this is possible when the population is one.

He Jiankui was not a fringe figure. He held a PhD from Rice University, had done postdoctoral work at Stanford, and was an associate professor at the Southern University of Science and Technology in Shenzhen. He had founded two genomics companies and was well-connected in China's rapidly growing biotech sector.

If you have been reading about genetic medicine, you have probably seen the terms "gene therapy" and "gene editing" used almost interchangeably. News headlines blur the line constantly. But these two approaches are fundamentally different — in how they work, what they can treat, and what they mean for patients.

Of all the organs in the human body, the eye may be the single best target for gene therapy and gene editing. This is not a coincidence — it is a convergence of biological properties that make the eye uniquely suited to these interventions, and it is why ophthalmology has led the field in clinical translation.

Wave Life Sciences has emerged as a leader in programmable RNA editing therapeutics. The company's ADAR-mediated editing platform uses stereopure antisense oligonucleotides — ASOs with precisely controlled stereochemistry at every phosphorothioate linkage — to recruit endogenous ADAR1 to specific RNA targets.

All compact Class 2 CRISPR effectors share the same basic biochemistry as SpCas9: an RNA guide directs the protein to a complementary DNA sequence flanked by a short protospacer-adjacent motif (PAM), the protein interrogates the DNA, and — if the match is good — it introduces a double-strand break or a nick.

As climate change drives temperatures higher, heat stress in cattle is becoming a serious agricultural problem. Heat-stressed cows eat less, produce less milk, gain weight more slowly, and suffer higher mortality rates. The economic losses in the United States alone run into the billions of dollars annually.

CRISPR agriculture is still in its early stages. The crops on the market today are mostly first-generation products with single-trait modifications. The next wave will involve more complex edits -- stacking multiple traits, modifying regulatory networks, and engineering entirely new metabolic capabilities.

The conceptual leap from COVID vaccines to CRISPR delivery is straightforward but profound. In a vaccine, LNPs carry mRNA that encodes a viral protein. In a gene-editing therapy, LNPs carry mRNA that encodes the Cas9 enzyme plus a synthetic guide RNA that directs Cas9 to a specific location in the genome.

The core technology behind most epigenetic editing platforms is a modified version of the CRISPR system. Standard CRISPR-Cas9 uses a guide RNA to direct the Cas9 protein to a specific genomic location, where Cas9 cuts both strands of DNA. Epigenetic editing replaces the cutting with chemical modification.

Rather than simply accepting SpCas9's mismatch tolerance, structural biologists and protein engineers have redesigned the enzyme to be more discriminating. The strategy is counterintuitive: make the enzyme slightly less active overall so that it only cleaves when the guide-target match is nearly perfect.

The landscape of gene editing clinical trials is evolving rapidly. The following represents a snapshot of notable trials that were recruiting or expected to begin recruitment as of early 2026. We recommend verifying current status on ClinicalTrials.gov, as enrollment windows can open and close quickly.

Excision BioTherapeutics, founded in 2015 and headquartered in San Francisco, was created specifically to translate Dr. Khalili's work into a clinical therapy. The company's lead product, EBT-101, is the first CRISPR-based gene editing therapy designed to cure HIV to enter human clinical trials.

One of the most celebrated results in the CRISPR cancer treatment landscape comes not from conventional CRISPR-Cas9 cutting but from base editing -- a more precise variant developed by David Liu at the Broad Institute that can change individual DNA letters without creating double-strand breaks.

Despite the scientific consensus, public attitudes toward gene-edited foods remain mixed. Surveys consistently show that a significant portion of consumers express unease about genetic modification in their food, often without distinguishing between transgenic GMOs and gene-edited products.

The modern era of ocular gene therapy began with Luxturna (voretigene neparvovec-rzyl), developed by Spark Therapeutics and approved by the FDA in December 2017. Luxturna was the first gene therapy approved in the United States for a genetic disease, and it remains a landmark in the field.

Perhaps no gene-editing project has captured the public imagination quite like the effort to de-extinct the woolly mammoth. Colossal Biosciences, founded in 2021 by tech entrepreneur Ben Lamm and Harvard geneticist George Church, has raised over $225 million to pursue this audacious goal.

The development of combination antiretroviral therapy in the mid-1990s was one of the great achievements of modern medicine. Before ART, an HIV diagnosis was effectively a terminal one. Today, people who begin treatment early and adhere to their regimen can expect a near-normal lifespan.

Caribou Biosciences, co-founded by Jennifer Doudna, has taken a differentiated approach to allogeneic CAR-T using its proprietary chRDNA (CRISPR hybrid RNA-DNA) technology, which the company says improves editing specificity by reducing off-target effects compared to standard guide RNAs.

There are diseases that strike suddenly, and there are diseases that dismantle a person gradually, stealing memories, personality, and independence over the course of years. Alzheimer's disease belongs to the second category, and it is among the cruelest afflictions in all of medicine.

The trend is unmistakable: smaller is better when delivery is the bottleneck. Scribe Therapeutics, co-founded by Jennifer Doudna, is building therapeutic editors around CasX. Mammoth Biosciences, also co-founded by Doudna, uses Cas12 and Cas14 enzymes for both diagnostics and editing.

The key advantage of CRISPRa over conventional gene therapy is that it uses the patient's own promoter, regulatory elements, and splicing machinery. The patient gets the right amount of the right isoform in the right cells — not a constitutively-expressed transgene that may overshoot.

Rather than delivering DNA or mRNA encoding Cas9, researchers can deliver the pre-assembled Cas9 protein complexed with its guide RNA as a ribonucleoprotein. RNPs are active immediately upon entering the cell and are degraded within hours, minimizing the window for off-target editing.

Before any experiment begins, researchers use computational tools to predict potential off-target sites for a given guide RNA. These tools are essential for guide selection — choosing the most specific guide from among candidates — and for nominating sites to validate experimentally.

The FDA has been cautiously supportive of xenotransplantation research. The first pig organ transplants in living patients were authorized under the compassionate use (expanded access) pathway, which allows unapproved treatments for seriously ill patients on a case-by-case basis.

Many endangered species face a genetic crisis: their populations are so small that inbreeding has reduced genetic diversity to dangerously low levels. This makes them vulnerable to disease, reduces reproductive success, and limits their ability to adapt to changing environments.

Here is where the story takes an unexpected turn. Despite producing arguably the most impressive first-in-human data for any gene editing therapy to date, Prime Medicine announced in early 2026 that it would wind down its CGD program. No additional patients would be enrolled.

The idea is deceptively simple. APOE4 and APOE2 differ by just two amino acid positions in the protein: position 112 and position 158. APOE4 has arginine at both positions. APOE3 has cysteine at position 112 and arginine at position 158. APOE2 has cysteine at both positions.

Base editing is furthest along in the clinic among the newer tools. Verve Therapeutics has advanced a base editing therapy targeting PCSK9 for cardiovascular disease, and Beam Therapeutics is running trials for sickle cell disease and acute leukemia using base-edited cells.

The story of in vivo gene editing is, in many ways, a story about delivery. The editing tools themselves — CRISPR-Cas9, base editors, prime editors — have been refined for years. The bottleneck has always been getting those tools to the right cells inside a living person.

While genetic engineering has largely solved hyperacute rejection, longer-term immunological challenges remain formidable. Patients who receive pig organs require intensive immunosuppressive therapy — often more aggressive than what is used for human-to-human transplants.

Before we can understand epigenetic editing, we need to understand what the epigenome actually is and how it works. If DNA is the hardware — the fixed instruction set encoded in every cell — then epigenetics is the software that determines which instructions are executed.

Viruses are nature's delivery vehicles. Over millions of years, they have evolved to efficiently enter human cells and deliver genetic cargo. Gene therapy has co-opted this capability by engineering viruses that carry therapeutic payloads instead of pathogenic ones.

While most of the compact-editor conversation has focused on making smaller versions of the Cas9-like single-protein effectors, a completely different branch of the CRISPR family tree offers an alternative approach: Type I CRISPR systems, which use the Cas3 enzyme.

Lonvo-z is not Intellia's only in vivo CRISPR program. The company's other lead candidate, nex-z (NTLA-2001), targets transthyretin amyloidosis (ATTR) -- a progressive, fatal disease caused by misfolded transthyretin protein that deposits in the heart and nerves.

To understand why access is so difficult, you first have to understand what the treatment demands of a patient. Casgevy is not a pill. It is not an infusion you receive at your local clinic. It is a months-long medical odyssey that requires uprooting your life.

One of the most challenging conceptual problems in the designer babies debate is distinguishing between therapeutic applications and enhancement. The line between treating disease and improving upon normal human traits is not as clear as it might first appear.

Why pursue epigenetic editing when CRISPR-Cas9, base editing, and prime editing already exist and have proven clinical utility? The answer lies in a set of unique advantages that make epigenetic editing the preferred approach for certain categories of disease.

When standard CRISPR-Cas9 reaches its target, it slices through both strands of the DNA double helix. This double-strand break is one of the most dangerous types of DNA damage a cell can experience. The cell scrambles to repair it using one of two pathways:

The IS110 recombinase is a serine recombinase — a class of enzymes long known to catalyze DNA strand exchange via a covalent serine-DNA intermediate. What was new in 2024 was the discovery that an RNA could direct this recombinase to programmable sites.

This is the question that matters most to people standing in the grocery aisle. The short answer is that the scientific consensus is clear: gene-edited foods currently on the market pose no known safety risks that differ from conventionally bred foods.

In October 2020, the Nobel Committee awarded the Nobel Prize in Chemistry to Jennifer Doudna and Emmanuelle Charpentier "for the development of a method for genome editing." The prize recognized their 2012 discovery of the CRISPR-Cas9 genetic scissors.

Base editing isn't perfect. It can only make certain types of changes (the four transitions mentioned above), and it sometimes edits nearby bases unintentionally — a phenomenon called "bystander editing." It also can't insert or delete DNA sequences.

The liver has been the proving ground for in vivo gene editing, but it won't be the only target for long. Researchers are actively developing delivery systems to reach other organs, and several programs are already in or approaching clinical trials.

While the U.S. proceedings dominated headlines, the battle played out differently at the European Patent Office (EPO). European patent law applies different standards for patentability, and the EPO's proceedings followed a different procedural path.

Off-target effects get the most attention, but there are other safety concerns inherent to any technology that deliberately cuts both strands of DNA. Even when CRISPR cuts at exactly the right place, the repair process itself can introduce problems.

Epigenetic dysregulation is a hallmark of cancer. Tumor suppressor genes are frequently silenced by aberrant promoter methylation, while oncogenes may be activated by loss of repressive marks. Epigenetic editing offers two complementary strategies:

Before CRISPR, genetic engineering in pigs was agonizingly slow. Creating a single gene knockout could take years of breeding. The idea of making dozens of precise edits to the pig genome was not merely difficult — it was practically impossible.

In April 2026, researchers funded by the National Institutes of Health (NIH) published results on what may be the most significant compact editor to date: an engineered variant of the naturally occurring Cas12f enzyme designated Al3Cas12f RKK.

Lonvo-z takes an entirely different approach. Rather than blocking one step of the kallikrein cascade with a drug that must be continuously replenished, it permanently removes the source of the problem by editing a single gene in the liver.

More than 100,000 people in the United States are on the waiting list for organ transplants, and roughly 17 people die each day waiting for an organ that never comes. The gap between supply and demand has grown steadily wider for decades.

Scribe Therapeutics is arguably the furthest along in clinical development with a compact editor platform. The company, based in Emeryville, California, has built its entire pipeline around engineered CasX variants. Key programs include:

The core architecture of most epigenetic editors follows a simple modular design: a DNA-targeting domain that navigates to a specific genomic address, fused to an effector domain that writes or erases an epigenetic mark once it arrives.

The emergence of RNA editing as a mature therapeutic modality does not mean DNA editing is obsolete. The two approaches have distinct strengths, and the choice between them depends on the disease, the patient, and the therapeutic goal.

Allogene Therapeutics has built its entire corporate strategy around allogeneic CAR-T, developing a platform called AlloCAR T that uses TALEN gene editing (developed by its partner Cellectis) for the foundational genetic modifications.

Perhaps the most astonishing aspect of N-of-1 therapies is the timeline. Traditional drug development takes 10 to 15 years from target identification to FDA approval. N-of-1 therapies compress this to an almost unrecognizable degree.

If any single company embodies the RNA editing moment of 2026, it is Wave Life Sciences. The Cambridge, Massachusetts-based company has built what may be the most advanced clinical-stage endogenous ADAR editing platform in the world.

RNA editing is not a human invention. It occurs naturally in every human cell, carried out by a family of enzymes called ADARs (Adenosine Deaminases Acting on RNA). Humans have two catalytically active ADAR enzymes: ADAR1 and ADAR2.

Despite the compelling logic, a gene editing cure for obesity faces formidable scientific, regulatory, and ethical challenges. It is important to be honest about how far away this possibility is and what obstacles stand in the path.

The idea of using donor T cells instead of the patient's own cells is conceptually straightforward, but immunologically perilous. Transplanting one person's T cells into another triggers two potentially lethal immune reactions:

In clinical research, "N" refers to the number of participants in a study. A phase III clinical trial might have N = 3,000. A small pilot study might have N = 20. An N-of-1 therapy has, as the name states, exactly one patient.

DeepMind's AlphaFold2, released in 2020, solved the decades-old problem of predicting protein three-dimensional structure from amino acid sequence. For the gene editing field, the implications were immediate and substantial.

The most important safety data come not from laboratory experiments but from clinical trials in actual patients. As of early 2026, several CRISPR-based and gene editing therapies have generated substantial human safety data.

Virus-like particles represent an emerging hybrid approach. VLPs are protein shells derived from viral capsids that mimic the structure of a virus but contain no viral genome. Instead, they are loaded with CRISPR RNP cargo.

A critical challenge in N-of-1 therapy is scalability. If every patient requires a completely novel drug, designed from scratch, the approach will remain boutique — a handful of cases per year, each requiring heroic effort.

While Wave and the adaptamer team are using RNA editing to fix or control gene expression, a third line of research is using it for an entirely different purpose: creating new targets for the immune system to attack cancer.

Gene editing is also reshaping agriculture. CRISPR allows scientists to make precise modifications to crop genomes without introducing foreign DNA — a key distinction from traditional genetic modification (GMO) techniques.

Casgevy takes an indirect but elegant approach. Rather than fixing the sickle mutation itself, it reactivates fetal hemoglobin — a form of hemoglobin that humans naturally produce before birth but switch off shortly after.

1. Two pegRNAs target opposite strands in proximity at a single locus. Each pegRNA contains a spacer (for Cas9 targeting), a primer-binding site, and a reverse-transcriptase template encoding the new sequence to write.

The therapeutic programs from Verve and CRISPR Therapeutics represent something more than incremental improvements in lipid management. They embody a fundamental shift in how we think about treating chronic disease.

CRISPR Therapeutics, co-founded by Nobel laureate Emmanuelle Charpentier, has arguably generated the most compelling clinical data in the allogeneic CAR-T space with its lead oncology candidate, zugo-cel (CTX112).

A lipid nanoparticle, or LNP, is a tiny sphere roughly 80 to 100 nanometers in diameter -- about one-thousandth the width of a human hair. It is composed of four lipid components, each serving a specific function:

The Phase 1/2 clinical trial of lonvo-z (study NTLA-2002-001) began dosing patients in late 2021 and has since produced what many in the field consider the most impressive dataset in CRISPR therapeutics to date.

The field has developed several distinct strategies for harnessing ADAR-mediated RNA editing therapeutically. Understanding the toolkit is essential for appreciating where each company and research group fits.

The global scientific community has responded to the prospect of heritable human genome editing through a series of international summits and policy statements, though consensus on the details remains elusive.

The Casgevy access crisis is not a problem with a single solution. It is a problem with multiple interlocking causes, each of which requires its own intervention. But several paths forward are becoming clear.

The convergence of gene editing technology, improved delivery systems, and deepening understanding of HIV biology has created genuine momentum toward a cure. Several developments to watch in the coming years:

The disability rights community has raised some of the most important and least heard voices in the designer babies debate. Their concerns challenge assumptions that many non-disabled people take for granted.

Despite their advantages, pig organs face three formidable biological barriers when placed inside a human body. Understanding these barriers is essential to appreciating why CRISPR has been so transformative.

To understand why He Jiankui's experiment provoked such alarm, it is essential to grasp the distinction between somatic and germline editing, because the ethical calculus for each is fundamentally different.

While CRISPR Therapeutics approaches T1D through iPSC-derived, gene-edited cells, Vertex Pharmaceuticals has pursued a parallel path that has generated some of the most compelling clinical data in the field.

If Wave Life Sciences represents the industrialization of RNA editing, adaptamers represent its most imaginative frontier: using RNA editing to build programmable, drug-responsive switches for gene therapy.

Here is one area where both approaches face similar headaches. Getting the editing machinery into the right cells inside a living patient is hard — regardless of whether that machinery cuts DNA or tags it.

While Verve focused on PCSK9, CRISPR Therapeutics — the company co-founded by Emmanuelle Charpentier, who shared the 2020 Nobel Prize for the discovery of CRISPR — took aim at a different target: ANGPTL3.

Gene therapy is the older of the two approaches. The core idea is simple: if a patient's body cannot make a critical protein because the gene responsible is broken, give them a working copy of that gene.

Regulatory agencies worldwide have established specific expectations for off-target characterization in gene-editing therapies. The requirements reflect a layered approach: cast a wide net, then verify.

Gene editing takes a different approach entirely. Instead of adding a new gene copy, it goes into the patient's existing DNA and makes a precise change — fixing, disabling, or altering a specific gene.

The compact editor landscape extends well beyond Al3Cas12f RKK and Cas3. Several other systems are in active development, each with distinct properties that make them suited to different applications.

Endogenous ADAR enzymes can only make A-to-I (functionally A-to-G) changes. While engineered variants are expanding the repertoire, the current toolkit is far narrower than what DNA editing offers.

All approved and in-development CRISPR therapies target somatic cells, meaning the edits affect only the treated patient and are not passed on to future generations. This is a critical distinction.

The results, first presented at the American Society of Hematology (ASH) annual meeting in December 2025 and subsequently published in the New England Journal of Medicine, told a remarkable story:

While the clinical programs at Verve and CRISPR Therapeutics focus on cardiovascular targets, academic researchers are already exploring gene editing approaches that aim more directly at obesity.

Perhaps the most remarkable subplot of this story is the commercial failure of bluebird bio despite holding three FDA-approved gene therapies — a feat no other company had achieved at the time.

Lipid nanoparticles gained worldwide recognition as the delivery vehicle for the Pfizer-BioNTech and Moderna COVID-19 mRNA vaccines. The same technology is now being adapted for gene editing.

The patent battle did not play out in a vacuum. Even as the legal proceedings unfolded, three major CRISPR therapeutics companies were founded, each aligned with one of the key scientists:

The diagnostic potential of CRISPR extends well beyond human medicine. In agriculture, rapid pathogen detection can mean the difference between saving a crop and losing an entire harvest.

Despite their different mechanisms, Casgevy and Lyfgenia impose a remarkably similar treatment journey on patients. Both are one-time therapies that require months of medical commitment.

The therapeutic vision is to harness the cell's own ADAR enzymes — or deliver engineered versions — to edit specific RNA transcripts on demand. Several approaches are under development.

CRISPR Therapeutics, the company co-founded by Nobel laureate Emmanuelle Charpentier, is pursuing its own metabolic gene editing programs — and the results are already making headlines.

To appreciate why gene editing for Alzheimer's matters, it helps to understand the current state of treatment and why existing approaches, while significant, remain profoundly limited.

Electroporation uses brief electrical pulses to create temporary pores in cell membranes, allowing CRISPR components to enter. It is the workhorse delivery method for ex vivo editing.

To appreciate why CRISPR diagnostics are significant, it helps to understand the limitations of the technology they aim to supplement -- and eventually, in some applications, replace.

The speed and scale of the COVID vaccine rollout provided something that decades of preclinical research could not: massive real-world safety and efficacy data for LNP-delivered mRNA.

Imagine you could open a book, find a single misspelled word among billions of letters, and correct it without tearing any pages. That is what prime editing does to the human genome.

To understand why lonvo-z represents such a significant advance, it is essential to distinguish between the two fundamental approaches to CRISPR therapy: ex vivo and in vivo editing.

In 2024, Intellia and Regeneron Pharmaceuticals entered a collaboration agreement for the co-development and co-commercialization of lonvo-z and nex-z. Under the terms of the deal:

Traditional CRISPR is essentially a binary tool. When you knock out a gene, it is off. When you correct a mutation, the gene works normally again. There is not much middle ground.

As in vivo gene editing trials accumulate data, a clearer picture of the safety profile is emerging. So far, the news has been largely reassuring — but important questions remain.

Before enrolling in any clinical trial, have a detailed conversation with your physician. Here are specific questions that will help you evaluate whether a trial is right for you:

The choice between autologous (patient-derived) and allogeneic (donor-derived) CAR-T is one of the defining questions in cell therapy today. The trade-offs are real on both sides.

To understand why gene editing represents such a significant advance, it is necessary to understand the specific biological challenges that T1D presents to any curative approach.

The lesson: size is necessary but not sufficient. The winners will be editors that combine compactness with competitive activity, permissive PAMs, and a clean regulatory path.

The BRILLIANCE trial and subsequent research have clarified several advantages that CRISPR-based editing holds over traditional AAV gene addition for certain retinal diseases:

Recognizing that double-strand breaks are the root cause of many safety concerns, researchers have developed editing technologies that modify DNA without cutting both strands.

The pivotal trial for Casgevy enrolled 44 patients aged 12 to 35 with severe sickle cell disease, defined as at least two VOCs per year. Results submitted to the FDA showed:

Acrs are unique in that they preserve normal Cas9 activity until the moment you want to shut it down. Other safety strategies trade activity for specificity from the start.

The regulatory framework surrounding gene editing therapies involves multiple layers of oversight designed to catch safety problems before, during, and after clinical use.

1. dCas9-VP64. The original. Four VP16 domains fused C-terminally to dCas9. Recruits the basal transcriptional machinery directly. Effective at some loci, weak at others.

The legal landscape for human germline editing varies significantly around the world, reflecting different cultural values, political systems, and regulatory traditions.

Before examining how gene editing aims to transform T1D treatment, it is important to acknowledge how far management technology has come -- and where its limits remain.

The CRISPR patent war was not confined to the original Cas9 technology. As the field advanced, new gene-editing approaches emerged — and with them, new patent battles.

For all its promise, the gene editing approach to cardiovascular disease faces challenges that are qualitatively different from those of traditional drug development.

If editing APOE4 in brain cells is scientifically straightforward, the engineering challenge of actually getting the editing machinery into the brain is anything but.

Despite the excitement surrounding the Heart-2 results, important questions remain before in vivo base editing can become a standard treatment for high cholesterol.

The success of NTLA-2001 opened the floodgates. Multiple companies are now running clinical programs that use LNP-delivered CRISPR or related editing technologies:

Based on the Heart-2 results, Verve and Eli Lilly are expected to advance VERVE-102 into a Phase 2 trial in the second half of 2026. This larger study will likely:

Following the PM359 proof of concept, Prime Medicine has pivoted its focus to in vivo liver diseases — larger patient populations with clear commercial potential.

You do not have to navigate this alone. Several organizations specialize in connecting patients with clinical trials and providing support throughout the process.

DNA is made up of four bases: adenine (A), thymine (T), cytosine (C), and guanine (G). They pair up — A with T, C with G. Base editors come in two main flavors:

DNA editing technologies aim to correct the genome itself. The three major approaches differ in their mechanisms but share the goal of making lasting changes.

Standard CRISPR-Cas9 creates double-strand breaks (DSBs) in DNA — essentially cutting both strands of the helix. While powerful, this approach has downsides:

Several companies are advancing RNA editing therapies toward and through clinical trials, establishing proof of concept for this approach in human patients.

The T1D cell therapy landscape extends beyond CRISPR Therapeutics and Vertex. Several other companies and academic groups are pursuing distinct strategies.

To understand why the field is racing toward allogeneic solutions, it helps to appreciate just how many things can go wrong with autologous manufacturing.

While Intellia has dominated the headlines, another company has quietly produced one of the most exciting in vivo gene editing datasets of the past year.

Before designing a gene editing therapy, researchers must identify which gene to edit. This target identification step is itself being transformed by AI.

If milasen proved the concept with antisense oligonucleotides, the case of KJ Muldoon — known publicly as Baby KJ — proved it could be done with CRISPR.

One of the most remarkable aspects of prime editing is how rapidly it has improved. Each generation addressed specific limitations of its predecessors.

Prime editing's safety profile deserves special attention because it directly addresses the most concerning risks of other gene editing approaches.

The epigenetic editing landscape in 2026 includes a mix of established biotech companies, newly funded startups, and leading academic laboratories.

While infectious disease was the first proving ground, CRISPR diagnostics are now pushing into a far larger clinical opportunity: cancer detection.

The Heart-2 data, first presented in early 2026, represent a landmark moment for the field of in vivo gene editing. Here is what the trial showed.

While in vivo gene editing advances, the world's first approved CRISPR therapy continues to evolve — and its next frontier is pediatric patients.

Gene therapy has a significant head start in the clinic. As of early 2026, there are more than 30 FDA-approved gene therapy products, including:

To understand why in vivo gene editing is such a milestone, you need to understand the two fundamental approaches to editing genes in people.

The terms "GMO" and "gene-edited" are often used interchangeably in casual conversation, but they describe fundamentally different processes.

The case for targeting PCSK9 is one of the most compelling examples of human genetics informing drug development in the history of medicine.

One of the most impactful yet under-appreciated advances in prime editing came not from improving the protein, but from protecting the RNA.

The application of gene editing to HIV raises several important ethical questions that the field must address as clinical programs advance.

Excision BioTherapeutics is not the only group pursuing gene editing as an HIV cure strategy. Several other approaches deserve attention.

Several major academic institutions are actively pursuing gene editing strategies for Alzheimer's and related neurodegenerative diseases.

What do the clinical data actually show? The results have been more reassuring than early fears predicted, though the picture is nuanced.

While epigenetic editing is still largely preclinical, several therapeutic areas are advancing rapidly toward translational milestones.

To understand why gene editing for obesity is plausible, it helps to look at what is already working for a related metabolic condition.

Understanding the practical reality of clinical trial participation is essential before you make a decision. Here is what to expect.

The UNSW fetal hemoglobin work highlights several broader advantages that epigenetic editing holds over conventional genome surgery.

To understand CRISPR diagnostics, you need to understand one key concept that separates detection from editing: collateral cleavage.

Reversibility is not always an advantage, and RNA editing has genuine limitations that make it unsuitable for some applications.

The most compelling evidence that HIV can be cured comes from two extraordinary cases that share a common thread: the CCR5 gene.

Understanding where prime editing fits in the gene editing toolkit requires comparing it directly to alternative technologies.

Note that Cas-CLOVER is larger in total protein mass but delivers a different value proposition (fidelity), not compactness.

The most significant differentiator between the two therapies is safety — specifically, the risk of hematologic malignancy.

Gene editing technologies offer two fundamentally different strategies for curing HIV, and researchers are pursuing both.

At its core, CRISPR-Cas9 is a molecular scissors system with two essential components: a guide RNA and the Cas9 protein.

For all its promise, RNA editing faces real obstacles that the field must overcome before it can fulfill its potential.

The practical outcome of the patent proceedings created an unusual and consequential division of intellectual property:

The prospect of gene editing for Alzheimer's prevention raises ethical questions that the field must confront honestly.

The reversible nature of RNA editing confers several practical and safety advantages over permanent DNA modification.

Different Acrs use very different strategies. The diversity is itself instructive — there is no single "off switch."

The distinction between CRISPR-edited crops and traditional GMOs is technically precise and politically significant.

The pace of in vivo gene editing development is accelerating. Here is what the field can expect in the near term.

Epigenetic editing is not without its challenges, and intellectual honesty demands that we address them directly.

The regulatory treatment of gene-edited crops is one of the starkest policy divergences between major economies.

If you have read our comprehensive guide to prime editing, you know the details. Here is the condensed version.

To understand why HIV is so difficult to cure, you need to understand how it operates at the molecular level.

Several persistent myths discourage patients from exploring clinical trials. Let us address them directly.

Cas13 has two HEPN ribonuclease domains that come together upon target binding. The mechanism is unusual:

The economic case for a one-time gene editing treatment for obesity is overwhelming. Consider the math.

Here is a side-by-side look at how the two approaches stack up across the dimensions that matter most.

CRISPR has moved from the laboratory bench to the clinic at a pace that few technologies have matched.

The modern era of N-of-1 gene therapy begins with a girl named Mila Makovec and a drug called milasen.

Before examining specific delivery vehicles, it helps to understand the two overarching approaches.

So, is CRISPR safe? Here is what an honest, evidence-based assessment looks like as of early 2026:

Beyond CGD, Wilson's disease, and AATD, Prime Medicine has disclosed several additional programs:

To appreciate what lonvo-z accomplishes, you first need to understand the disease it targets.

Gene-edited foods are not a hypothetical future. Several are already available to consumers.

The delivery field is advancing rapidly. Additional strategies under investigation include:

This is where CRISPR enters the story -- and where the field makes its most ambitious leap.

CRISPRi is not a finished technology. Several limitations matter for clinical translation:

Here is how gene therapy and gene editing stack up across the factors that matter most:

Understanding prime editing requires placing it in context with its predecessors.

Prime editing uses three molecular components working in precise coordination:

For a primer on the cutting version, see What Is CRISPR? The Complete Guide.

Permanent DNA editing remains the superior approach in several scenarios:

To put gene editing in context, it helps to understand the alternatives.

Prime editing's versatility extends far beyond single-base corrections.

The simplest way to grasp the distinction is through two analogies.

The maturity gap between the two approaches is significant in 2026.

Several CRISPR-edited food products have already reached consumers:

The economics of N-of-1 therapy are, to put it mildly, challenging.

Gene therapy is often the better choice in certain situations:

Gene editing has distinct advantages in other scenarios:

Both approaches are expensive — and controversially so.

RNA editing has clear advantages in other scenarios:

Five features distinguish Cas12a from Cas9:

The classical workflow has three steps:

The mechanism unfolds in three layers:

Three properties matter for therapy: